Compare Expedia Group Inc (EXPE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Zoetis Inc — how do they compare? Expedia Group Inc trades at $274.22 (market cap $32.42B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Expedia Group Inc and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Zoetis Inc for 70 Days on average.
| EXPE | ZTS | |
|---|---|---|
Market Cap | $32.42B | $30.20B |
Volume | 1,940,671 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $147.53 |
52-Week Low | $188.51 | $69.09 |
Typical Hold Time | 47 Days | 70 Days |
Enterprise Value | $30.98B | $37.76B |
Dividend Yield | 0.71% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 4.35% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90.43% gross margins, and improving cash flow trends. Recent news highlights competitive threats from AI travel agents but also strategic partnerships and positive growth outlook. Analyst consensus remains mixed with a $335.06 price target representing 24% upside potential from current levels.
Expedia presents a compelling value opportunity with reasonable valuation multiples (P/E 16.99, P/S 2.18) and strong profitability metrics. However, investors face significant competitive risks from AI disruption and recent layoffs indicate operational challenges. The stock's upside depends on maintaining booking growth momentum against increasing industry competition and technological disruption.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
